The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Genomics defines neoplastic transformation in multiple myeloma precursor conditions
In this video, Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the concept of using genomics to define neoplastic transformation in multiple myeloma precursor conditions, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Dr Maura highlights that genomic data may be used to identify transformation and assess the risk of progression. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
